MTDHP2

Across TCGA pan-cancer cohorts, MTDHP2 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated MTDHP2 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher MTDHP2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated MTDHP2 expression acts as an unfavorable survival marker, although some lineages such as MESO and LUAD show a favorable association.

MESO, LUAD, and LUSC are the cancer types where MTDHP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.516	0.286	<.001	144	view →
LUAD	DFS	Tertile	All	0.871	0.765	.002	108	view →
LUSC	DFS	Tertile	All	0.648	0.779	<.001	72	view →
KICH	DFS	Median	All	1.000	0.697	<.001	35	view →
LIHC	DFS	Tertile	All	0.289	0.452	.009	27	view →
COAD	DFS	Tertile	IV	0.159	0.503	.006	18	view →
BRCA	DFS	Tertile	IV	0.368	0.802	.004	18	view →
READ	DFS	Tertile	IV	0.027	0.636	<.001	18	view →
PAAD	DFS	Tertile	III,IV	0.152	0.821	.045	9	view →
ACC	OS	Tertile	III,IV	1.000	0.495	.041	6	view →
THCA	OS	Median	II,III,IV	0.964	1.000	.018	5	view →
KIRP	DFS	Tertile	All	0.953	0.887	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

MTDHP2–MESO (OS)

Open the MESO breakdown →